An Emerging Specialty Pharmaceutical Business.

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa combines the energy and innovation of a new venture with the resources of a leading, diversified pharmaceutical company. Our primary focus is on supportive care for patients that are often critically ill. These therapeutics help manage complications from their illnesses or from the treatments they are receiving for those illnesses. Drawing on years of experience in the specialty pharmaceutical arena, our team of professionals has the resources to prepare products for launch and to help ensure their ongoing success.

Specialty focus supported by the wide-ranging resources of a leading pharmaceutical company – this is what makes Strativa unique. It is also what makes us an ideal partner for specialty and biotech companies ready to develop and commercialize new compounds.

Our creed
At Strativa, we are dedicated to improving patients’ lives, servicing our customers, supporting our colleagues, and rewarding our shareholders. As part of Par Pharmaceutical, we share a common creed that is the inspiration for everything we do:

WE ANSWER TO PATIENTS to whom more than one million Par prescriptions are dispensed each week in the U.S. Therefore, we will assure our products are scientifically sound and of uncompromising quality. In a world with significant unmet medical needs, we will always remember that the patient is waiting for new medicines. Our research and development and strategic initiatives will be focused on promptly meeting patient needs.

WE ANSWER TO CUSTOMERS: Our customer service must meet precision standards. Orders must be filled promptly, accurately and completely. We will work tirelessly and continuously with our trade partners to improve and streamline logistics. The patient is waiting.

WE ANSWER TO COLLEAGUES: At Par, our most important resource is human imagination. We will help our colleagues improve their skills and realize their potential. We will reward value-adding performance and strive to develop and nurture a climate that encourages collaboration and trust.

WE ANSWER TO SHAREHOLDERS and will provide a fair return on their investment in our business, rewarding the trust they have placed in us.


News about us

February 5, 2010
Strativa Pharmaceuticals Provides An Update On Zuplenz®(ondansetron) Oral Soluble Film

February 2, 2010
Par Pharmaceutical Companies To Report Fourth Quarter And Full Year 2009 Results On February 24, 2010

November 25, 2009
Par Pharmaceutical Announces Results of its “Modified Dutch Auction” Tender Offer

November 16, 2009
Par Pharmaceutical To Host Analyst Day On December 3rd

Par Pharmaceutical Receives Final Approval To Market Generic Ultram® ER

November 09, 2009
Par Announces Extension and Increase in Maximum Purchase Price for "Modified Dutch Auction" Tender Offer to Purchase up to $65,000,000

November 06, 2009
Par Pharmaceutical Reports EPS Of $0.76 For Third Quarter 2009

October 22, 2009
Par Pharmaceutical To Host Third Quarter 2009 Earnings Conference Call On November 6 At 9:00 AM

October 14, 2009
Par Announces “Modified Dutch Auction” Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010

September 14, 2009
Strativa Pharmaceuticals’ Development Partner, Bioalliance Pharma, Presents Phase III Study Results Of Miconazole Lauriad® For The Treatment Of Oropharyngeal Candidiasis

September 10, 2009
Par Pharmaceutical Receives Final Approval To Market Generic Starlix®

August 19, 2009
FDA Accepts Drug Application For Miconazole Lauriad® To Treat Oropharyngeal Candidiasis

August 18, 2009
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval To Market Generic Catapres TTS®

August 17, 2009
Par Pharmaceutical Wins On Invalidity In Ultram® ER Litigation

August 4, 2009
Par Pharmaceutical Reports EPS Of $0.71 For Second Quarter 2009

July 15, 2009
Par To Host Second Quarter 2009 Earnings Conference Call On August 4 At 9:00 AM

June 16, 2009
Strativa’s Development Partner, Bioalliance Pharma, Submits Loramyc® NDA

June 12, 2009
Thomas P. Rice Elected To Board Of Directors Of Par Pharmaceutical Companies, Inc.

June 10, 2009
Strativa’s New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA

June 9, 2009
Par Pharmaceutical Begins Shipment Of Generic Miacalcin®

June 2, 2009
Par Pharmaceutical Begins Shipment Of Generic Risperdal® M-TAB

May 6, 2009
Par Pharmaceutical Reports Adjusted EPS Of $0.49 For First Quarter 2009

April 29, 2009
Par Pharmaceutical To Host First Quarter 2009 Earnings Conference Call On May 6 At 9:00 AM

April 21, 2009
Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals To Settle Patent Litigation Over Rythmol® SR

April 9, 2009
Strativa Pharmaceuticals Provides Product Pipeline Update

April 1, 2009
Strativa Pharmaceuticals Acquires Worldwide Rights To Nascobal® (Cyanocobalamin, USP) Nasal Spray From QOL Medical

March 2, 2009
Par Pharmaceutical Reports Fourth Quarter And Full Year 2008 Results

February 25, 2009
Par Pharmaceutical To Host Fourth Quarter And Full Year 2008 Results Conference Call On March 3 At 9:00 AM

February 2, 2009
Federal Trade Commission Files Complaint Against Par Over Court-Approved Androgel® Litigation Settlement

January 7, 2009
Par Pharmaceutical To Present At The 27th Annual J.P. Morgan Healthcare Conference

December 12, 2008
Par Pharmaceutical Announces The Resignation Of Its Chief Financial Officer

December 02, 2008
Strativa Pharmaceuticals Announces Successful Completion Of Bioequivalence Studies For Ondansetron Thin Film

November 06, 2008
Par Pharmaceutical Reports Third Quarter 2008 Results

October 28, 2008
Par Pharmaceutical To Host Third Quarter 2008 Results Conference Call On November 7 At 9:00 AM

October 14, 2008
Par Pharmaceutical Announces Resizing Of Generic Unit To Optimize Strong First-To-File Pipeline

Gerard A. Martino Resigns As Chief Operating Officer

August 07, 2008
Par Pharmaceutical Reports Second Quarter 2008 Results

July 29, 2008
Par Pharmaceutical To Host Second Quarter 2008 Results Conference Call On August 8 At 9:00 AM

June 17, 2008
Strativa Pharmaceuticals Acquires Commercialization Rights To Thin Film Formulation Of Ondansetron From Monosol Rx

May 29, 2008
Strativa Pharmaceuticals Announces Preliminary Results From Onconase® Phase IIIb Clinical Trial

May 08, 2008
Par Pharmaceutical Reports First Quarter 2008 Results

April 21, 2008
Strativa Pharmaceuticals Announces Phase III Results For Loramyc® to Treat Oropharyngeal Candidiasis

February 25, 2008
Strativa Pharmaceuticals Announces the Discontinuation of the Development Program for Pafuramidine

January 15, 2008
Strativa Pharmaceuticals Acquires Commercialization Rights To Onconase® From Alfacell Corporation

September 28, 2007
Introducing Strativa Pharmaceuticals

August 09, 2007
Patrick G. LePore Elected Chairman of Board of Directors, Joseph E. Smith Named Lead Director of Par Pharmaceutical Companies, Inc.

August 02, 2007
Par Pharmaceutical Announces Equity Investment in Intellipharmaceutics LTD.

August 01, 2007
Par Pharmaceutical Licenses North American Rights to Zensana™ from Hana Biosciences

July 30, 2007
Par Pharmaceutical Files Form 10-Q/A for Third Quarter of 2006

July 10, 2007
Par Pharmaceutical Files Form 10-Q/As for First and Second Quarters of 2006

July 03, 2007
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc™ From Bioalliance Pharma


Meet Strativa Pharmaceuticals Go to the PAR Pharmaceuticals, Inc. website